(ARGX) argenx - Overview
Exchange: NASDAQ •
Country: Netherlands •
Currency: USD •
Type: Common Stock •
ISIN: US04016X1019
Stock: Biologics, Treatments, Autoimmune
Total Rating 53
Risk 53
Buy Signal -0.73
| Risk 5d forecast | |
|---|---|
| Volatility | 39.0% |
| Relative Tail Risk | -16.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.45 |
| Alpha | 9.71 |
| Character TTM | |
|---|---|
| Beta | 0.220 |
| Beta Downside | 0.065 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.20% |
| CAGR/Max DD | 0.76 |
EPS (Earnings per Share)
Revenue
Description: ARGX argenx March 04, 2026
argenx SE is a commercial-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Its primary products, VYGART and VYGART HYTRULO, address conditions such as generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). The biopharmaceutical sector is characterized by high research and development costs and a lengthy drug approval process.
The companys pipeline includes efgartigimod for various autoimmune indications like thyroid eye diseases and lupus nephropathy, and empasiprubart for conditions such as multifocal motor neuropathy and dermatomyositis. argenx also has early-stage programs, including ARGX-119 for neurological disorders and ARGX-109 for inflammation. Biopharmaceutical companies often rely on strategic collaborations to share development risks and expand market reach, as evidenced by argenxs numerous partnerships.
Further research on platforms like ValueRay can provide detailed financial metrics and competitive analysis for ARGX.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 12.03 > 1.0 |
| NWC/Revenue: 113.7% < 20% (prev 142.9%; Δ -29.24% < -1%) |
| CFO/TA 0.07 > 3% & CFO 479.8m > Net Income 1.62b |
| Net Debt (-2.04b) to EBITDA (844.1m): -2.42 < 3 |
| Current Ratio: 5.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.7m) vs 12m ago 10.53% < -2% |
| Gross Margin: 77.07% > 18% (prev 0.91%; Δ 7616 % > 0.5%) |
| Asset Turnover: 70.36% > 50% (prev 54.91%; Δ 15.45% > 0%) |
| Interest Coverage Ratio: 156.2 > 6 (EBITDA TTM 844.1m / Interest Expense TTM 3.96m) |
Altman Z'' 3.50
| A: 0.67 (Total Current Assets 5.83b - Total Current Liabilities 1.04b) / Total Assets 7.18b |
| B: -0.16 (Retained Earnings -1.16b / Total Assets 7.18b) |
| C: 0.10 (EBIT TTM 618.3m / Avg Total Assets 5.99b) |
| D: -0.99 (Book Value of Equity -1.07b / Total Liabilities 1.08b) |
| Altman-Z'' Score: 3.50 = A |
Beneish M -1.70
| DSRI: 1.14 (Receivables 1.20b/655.6m, Revenue 4.21b/2.63b) |
| GMI: 1.18 (GM 77.07% / 90.95%) |
| AQI: 1.75 (AQ_t 0.18 / AQ_t-1 0.10) |
| SGI: 1.60 (Revenue 4.21b / 2.63b) |
| TATA: 0.16 (NI 1.62b - CFO 479.8m) / TA 7.18b) |
| Beneish M-Score: -1.70 (Cap -4..+1) = CCC |
What is the price of ARGX shares?
As of March 06, 2026, the stock is trading at USD 728.11 with a total of 414,220 shares traded.
Over the past week, the price has changed by -5.63%, over one month by -11.24%, over three months by -19.20% and over the past year by +14.39%.
Over the past week, the price has changed by -5.63%, over one month by -11.24%, over three months by -19.20% and over the past year by +14.39%.
Is ARGX a buy, sell or hold?
argenx has received a consensus analysts rating of 4.59.
Therefore, it is recommended to buy ARGX.
- StrongBuy: 14
- Buy: 7
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARGX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1034.2 | 42% |
| Analysts Target Price | 1034.2 | 42% |
ARGX Fundamental Data Overview March 02, 2026
P/E Trailing = 32.8024
P/E Forward = 26.1097
P/S = 11.1721
P/B = 7.7828
P/EG = 0.8469
Revenue TTM = 4.21b USD
EBIT TTM = 618.3m USD
EBITDA TTM = 844.1m USD
Long Term Debt = 43.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 43.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.04b USD (from netDebt column, last quarter)
Enterprise Value = 43.57b USD (47.46b + Debt 43.2m - CCE 3.93b)
Interest Coverage Ratio = 156.2 (Ebit TTM 618.3m / Interest Expense TTM 3.96m)
EV/FCF = 92.02x (Enterprise Value 43.57b / FCF TTM 473.5m)
FCF Yield = 1.09% (FCF TTM 473.5m / Enterprise Value 43.57b)
FCF Margin = 11.24% (FCF TTM 473.5m / Revenue TTM 4.21b)
Net Margin = 38.57% (Net Income TTM 1.62b / Revenue TTM 4.21b)
Gross Margin = 77.07% ((Revenue TTM 4.21b - Cost of Revenue TTM 965.9m) / Revenue TTM)
Gross Margin QoQ = 90.29% (prev 88.32%)
Tobins Q-Ratio = 6.07 (Enterprise Value 43.57b / Total Assets 7.18b)
Interest Expense / Debt = 2.30% (Interest Expense 993.0k / Debt 43.2m)
Taxrate = 10.83% (41.8m / 386.1m)
NOPAT = 551.4m (EBIT 618.3m * (1 - 10.83%))
Current Ratio = 5.60 (Total Current Assets 5.83b / Total Current Liabilities 1.04b)
Debt / Equity = 0.01 (Debt 43.2m / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = -2.42 (Net Debt -2.04b / EBITDA 844.1m)
Debt / FCF = -4.31 (Net Debt -2.04b / FCF TTM 473.5m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 27.14% (Net Income 1.62b / Total Assets 7.18b)
RoE = 32.57% (Net Income TTM 1.62b / Total Stockholder Equity 4.99b)
RoCE = 12.29% (EBIT 618.3m / Capital Employed (Equity 4.99b + L.T.Debt 43.2m))
RoIC = 9.51% (NOPAT 551.4m / Invested Capital 5.80b)
WACC = 6.73% (E(47.46b)/V(47.50b) * Re(6.73%) + D(43.2m)/V(47.50b) * Rd(2.30%) * (1-Tc(0.11)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 6.42%
[DCF] Terminal Value 76.42% ; FCFF base≈473.5m ; Y1≈310.8m ; Y5≈141.8m
[DCF] Fair Price = 91.27 (EV 3.61b - Net Debt -2.04b = Equity 5.65b / Shares 61.9m; r=6.73% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 94.40 | EPS CAGR: 207.1% | SUE: 0.53 | # QB: 0
Revenue Correlation: 45.08 | Revenue CAGR: 173.1% | SUE: 1.33 | # QB: 2
EPS next Quarter (2026-06-30): EPS=5.07 | Chg7d=-1.402 | Chg30d=-1.542 | Revisions Net=+1 | Analysts=12
EPS current Year (2026-12-31): EPS=21.64 | Chg7d=-4.436 | Chg30d=-4.669 | Revisions Net=-4 | Growth EPS=+30.5% | Growth Revenue=+38.5%
EPS next Year (2027-12-31): EPS=29.48 | Chg7d=-2.337 | Chg30d=-2.774 | Revisions Net=-3 | Growth EPS=+36.2% | Growth Revenue=+21.7%
[Analyst] Revisions Ratio: +0.20 (3 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 7.9% - Earnings Yield 3.0%)
[Growth] Growth Spread = +41.2% (Analyst 46.1% - Implied 4.9%)
P/E Forward = 26.1097
P/S = 11.1721
P/B = 7.7828
P/EG = 0.8469
Revenue TTM = 4.21b USD
EBIT TTM = 618.3m USD
EBITDA TTM = 844.1m USD
Long Term Debt = 43.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 43.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.04b USD (from netDebt column, last quarter)
Enterprise Value = 43.57b USD (47.46b + Debt 43.2m - CCE 3.93b)
Interest Coverage Ratio = 156.2 (Ebit TTM 618.3m / Interest Expense TTM 3.96m)
EV/FCF = 92.02x (Enterprise Value 43.57b / FCF TTM 473.5m)
FCF Yield = 1.09% (FCF TTM 473.5m / Enterprise Value 43.57b)
FCF Margin = 11.24% (FCF TTM 473.5m / Revenue TTM 4.21b)
Net Margin = 38.57% (Net Income TTM 1.62b / Revenue TTM 4.21b)
Gross Margin = 77.07% ((Revenue TTM 4.21b - Cost of Revenue TTM 965.9m) / Revenue TTM)
Gross Margin QoQ = 90.29% (prev 88.32%)
Tobins Q-Ratio = 6.07 (Enterprise Value 43.57b / Total Assets 7.18b)
Interest Expense / Debt = 2.30% (Interest Expense 993.0k / Debt 43.2m)
Taxrate = 10.83% (41.8m / 386.1m)
NOPAT = 551.4m (EBIT 618.3m * (1 - 10.83%))
Current Ratio = 5.60 (Total Current Assets 5.83b / Total Current Liabilities 1.04b)
Debt / Equity = 0.01 (Debt 43.2m / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = -2.42 (Net Debt -2.04b / EBITDA 844.1m)
Debt / FCF = -4.31 (Net Debt -2.04b / FCF TTM 473.5m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 27.14% (Net Income 1.62b / Total Assets 7.18b)
RoE = 32.57% (Net Income TTM 1.62b / Total Stockholder Equity 4.99b)
RoCE = 12.29% (EBIT 618.3m / Capital Employed (Equity 4.99b + L.T.Debt 43.2m))
RoIC = 9.51% (NOPAT 551.4m / Invested Capital 5.80b)
WACC = 6.73% (E(47.46b)/V(47.50b) * Re(6.73%) + D(43.2m)/V(47.50b) * Rd(2.30%) * (1-Tc(0.11)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 6.42%
[DCF] Terminal Value 76.42% ; FCFF base≈473.5m ; Y1≈310.8m ; Y5≈141.8m
[DCF] Fair Price = 91.27 (EV 3.61b - Net Debt -2.04b = Equity 5.65b / Shares 61.9m; r=6.73% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 94.40 | EPS CAGR: 207.1% | SUE: 0.53 | # QB: 0
Revenue Correlation: 45.08 | Revenue CAGR: 173.1% | SUE: 1.33 | # QB: 2
EPS next Quarter (2026-06-30): EPS=5.07 | Chg7d=-1.402 | Chg30d=-1.542 | Revisions Net=+1 | Analysts=12
EPS current Year (2026-12-31): EPS=21.64 | Chg7d=-4.436 | Chg30d=-4.669 | Revisions Net=-4 | Growth EPS=+30.5% | Growth Revenue=+38.5%
EPS next Year (2027-12-31): EPS=29.48 | Chg7d=-2.337 | Chg30d=-2.774 | Revisions Net=-3 | Growth EPS=+36.2% | Growth Revenue=+21.7%
[Analyst] Revisions Ratio: +0.20 (3 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 7.9% - Earnings Yield 3.0%)
[Growth] Growth Spread = +41.2% (Analyst 46.1% - Implied 4.9%)